A new study details how a nasal spray formulated by investigators from Brigham and Women's Hospital may work to protect ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

Dr. Jeremy Farrar, WHO’s Chief Scientist, emphasized the importance of strengthening country-led R&D and integrating clinical ...

Huadong Medicine Co. Ltd. recently revealed data from in vitro and preclinical studies performed to evaluate the efficacy and pharmacokinetic, safety and tolerability profiles of a dual glucagon-like ...

Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

Scientists have uncovered critical differences between how innate-like T cells mature in humans and mice. Early in life, most innate-like T cells in the human thymus aren't able to use all of their ...

Men and women don’t experience pain the same way. Give someone an electric shock; bind a tourniquet tighter and tighter ...

Researchers at Duke-NUS Medical School have discovered that interleukin-11 (IL11) plays a crucial role in the aging process, ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.